Current Psychopharmacology
Title:Editorial [Hot Topic New Clinical Indications of Antipsychotic Medications Guest Editors: Filippo Bogetto and Silvio Bellino]
Volume: 2
Author(s): Filippo Bogetto and Silvio Bellino
Affiliation:
Export Options
About this article
Cite this article as:
Bogetto Filippo and Bellino Silvio, Editorial [Hot Topic New Clinical Indications of Antipsychotic Medications Guest Editors: Filippo Bogetto and Silvio Bellino], Current Psychopharmacology 2013; 2 (1) . https://dx.doi.org/10.2174/2211556011302010003
DOI https://dx.doi.org/10.2174/2211556011302010003 |
Print ISSN 2211-5560 |
Publisher Name Bentham Science Publisher |
Online ISSN 2211-5579 |
Call for Papers in Thematic Issues
Breakthroughs in drug design, development and delivery system for the management of neuro-psychiatric disorders
Neuropsychiatric diseases are one of the main causes of disability, affecting millions of people. Various drugs are used for its treatment, although no effective therapy has been found yet. The blood brain barrier (BBB) significantly complicates drugs delivery to the target cells in the brain tissues. This proposal describes the ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Understanding Epigenetic Alterations in Alzheimer's and Parkinson's Disease: Towards Targeted Biomarkers and Therapies
Current Pharmaceutical Design Small Molecule TGF-beta Mimetics as Potential Neuroprotective Factors
Current Alzheimer Research Protective Effects of Polydatin Against Dementia-Related Disorders
Current Neuropharmacology Chromosome 17 in Fronto Temporal Lobak Degeneration (FTLD): From MAPT to Progranulin and Back
Current Alzheimer Research How to Get from Here to There: Macrophage Recruitment in Alzheimers Disease
Current Alzheimer Research Lower Uric Acid Linked with Cognitive Dysfunction in the Elderly
CNS & Neurological Disorders - Drug Targets Poor Safety and Tolerability Hamper Reaching a Potentially Therapeutic Dose in the Use of Thalidomide for Alzheimer’s Disease: Results from a Double-Blind, Placebo-Controlled Trial
Current Alzheimer Research Recent Advances in the Medicinal Chemistry of Sodium Channel Blockers and their Therapeutic Potential
Current Topics in Medicinal Chemistry Cholinergic System and Neuroinflammation: Implication in Multiple Sclerosis
Central Nervous System Agents in Medicinal Chemistry Kv1.3 Lymphocyte Potassium Channel Inhibition as a Potential Novel Therapeutic Target in Acute Ischemic Stroke
CNS & Neurological Disorders - Drug Targets Systems Biology Approaches and Metabolomics for Understanding Japanese Traditional Kampo Medicine
Current Pharmacogenomics and Personalized Medicine Epidemiology and Risk Factors of Cerebral Ischemia and Ischemic Heart Diseases: Similarities and Differences
Current Cardiology Reviews Molecular Imaging of Apoptosis In Vivo with Scintigraphic and Optical Biomarkers – A Status Report
Anti-Cancer Agents in Medicinal Chemistry Acetylcholinesterase Inhibitors as Disease-Modifying Therapies for Alzheimers Disease
Current Medicinal Chemistry Targeting of α7 Nicotinic Acetylcholine Receptors in the Treatment of Schizophrenia and the Use of Auditory Sensory Gating as a Translational Biomarker
Current Pharmaceutical Design Chronic Infusion of Amyloid-β Peptide and Sustained Attention Altered α7 Nicotinic Receptor Density in the Rat Brain
Current Alzheimer Research Depressed or Demented: Common CNS Drug Targets? !
Current Drug Targets - CNS & Neurological Disorders Recent updates on the dynamic association between oxidative stress and neurodegenerative disorders
CNS & Neurological Disorders - Drug Targets Advancing Drug Therapy for Brain Tumours: A Current Review of the Pro-inflammatory Peptide Substance P and its Antagonists as Anti-cancer Agents
Recent Patents on CNS Drug Discovery (Discontinued) Neuroprotection by Association of Palmitoylethanolamide with Luteolin in Experimental Alzheimer’s Disease Models: The Control of Neuroinflammation
CNS & Neurological Disorders - Drug Targets